FDA Rejects Summit's Ivonescimab Lung Cancer Filing Over Survival Data
Summit Therapeutics says the FDA handed back its ivonescimab application for previously treated lung cancer, and the overall-survival numbers are the reason. The Phase III HARMONi trial hit its progression-free survival goal but missed statistical significance on overall survival.
- 3 sources report it: casrai.org, morningstar.com, hoodline.com.
- The source published it on Nov 15, 2026 at 10:03 AM.
Nothing open. Every check passed.
Summit Therapeutics said on November 15, 2026 that the US Food and Drug Administration issued a complete response letter for its ivonescimab application in previously treated lung cancer. In the company's statement, carried by Business Wire, the filing cannot be approved as it stands because the overall-survival evidence did not clear the agency's bar. Reuters and BioSpace both reported the decision the same day.
The application sought approval for ivonescimab paired with platinum-containing chemotherapy in locally advanced or metastatic non-small cell lung cancer, for patients who had already received an EGFR tyrosine kinase inhibitor. The data came from HARMONi, a global, randomized, double-blind Phase III study with two primary endpoints: progression-free survival and overall survival.
Summit reported that HARMONi met its progression-free survival endpoint, but the primary overall-survival analysis came in without statistical significance. According to the company, the FDA viewed that progression-free survival win as not enough to establish a positive benefit-risk profile on its own.
The FDA describes a complete response letter as what it sends when an application cannot be approved in its current form; the letter lays out the deficiencies found in review and may suggest steps toward marketing approval. Summit said it plans to keep pushing its broader ivonescimab development program.
TopicsSummit Therapeutics · FDA · ivonescimab · HARMONi · EGFR · Reuters · BioSpace · Business Wire
Written by AI from verified reporting. Not financial advice.
More stories
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
- Health & science casrai.org 0 viewsFDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
- Health & science nbcnews.com Caught by @nina.anggraini29 0 viewsMeasles Is Endemic Again as the U.S. Loses Its Elimination Status
- Health & science aol.com 1 viewFDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo

